Company / Cash & Equivalents
VOLITIONRX LTD Cash & Equivalents History
FY2012-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$3.3M
FY2024
5-year range
$3.3M / $20.7M
FY2020-FY2024
Trend
-84.3%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 6 years, ranging from $347,892 in FY2012 to $21M in FY2023.
Based on SEC 10-K filings.
$3M in FY2024 with a 3-year CAGR of -44.8%.
Declined from $11M to $3M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -44.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -44.8%, indicating a declining trend.
- In FY2024, cash & equivalents decreased 84.3% year-over-year.
- Peak cash & equivalents was recorded in FY2023.
- Lowest cash & equivalents in the period was in FY2012.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -13.39 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $3.3M | -84.3% |
| FY2023 | $20.7M | +90.8% |
| FY2022 | $10.9M | -44.1% |
| FY2021 | $19.4M | +14.6% |
| FY2020 | $17.0M | - |
| FY2019 | - | - |
| FY2014 | - | - |
| FY2013 | - | - |
| FY2012 | $347.9K | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026